Study Of Asthma In Patients Of African Descent

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: February 1, 2005
Last updated: April 15, 2015
Last verified: April 2015

February 1, 2005
April 15, 2015
November 2004
April 2007   (final data collection date for primary outcome measure)
Asthma exacerbation rate per patient per year
Not Provided
Complete list of historical versions of study NCT00102765 on Archive Site
Morning peak flow measurement, percent of asthma symptom-free days, percent of albuterol-free days
Not Provided
Not Provided
Not Provided
Study Of Asthma In Patients Of African Descent
A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone
This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)
Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Drug: fluticasone propionate/salmeterol powder
  • Drug: fluticasone propionate powder
    Other Name: fluticasone propionate/salmeterol powder
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2007
April 2007   (final data collection date for primary outcome measure)

Inclusion criteria:

  • History of asthma for at least 6 months.
  • Taking a low-dose of an inhaled corticosteroid for at least one month prior to the study (such as fluticasone propionate or budesonide).

Exclusion criteria:

  • History of life-threatening asthma.
  • Hospitalized for asthma within 3 months prior to the study.
  • Current respiratory tract infection.
  • Will not be able to attend clinic visits for the entire length of the study.
  • Certain medical conditions that will make being in the study unsafe (such as congestive heart failure, uncontrolled hypertension, tuberculosis or certain drug allergies).
12 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP